Targeted interventions for difficult-to-treat asthma

Bibliography

• ROBINSON DS, CAMPBELL DA, DURHAM SR, PFEFFER J, BARNES PJ, CHUNG KF: Systematic assessment of difficult-to-treat asthma. Eur. Respir. J. (2003) 22:478-483.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. (2004) 170:836-844.
   PubMed Web of Science ®Google Scholar
• RABE KF, VERMEIRE PA, SORIANO JB, MAIER WC: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. (2000) 16:802-807.
   PubMed Web of Science ®Google Scholar
• RABE KF, ADACHI M, LAI CKW et al.: Worldwide severity and control of asthma in children and adults: The global Asthma Insights and Reality surveys. J. Allergy Clin. Immunol. (2004) 114:40-47.
   PubMed Web of Science ®Google Scholar
• DOLAN CM, FRAHER KE, BLEEKER ER et al.: Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann. Allergy Asthma Immunol. (2004) 92:32-39.
   PubMed Web of Science ®Google Scholar
• SULLIVAN SD: The burden of uncontrolled asthma on the US health care system. Manag. Care (2005) 14:4-7.
   PubMedGoogle Scholar
• BOULET LP, PHILLIPS R, O’BYRNE P et al.: Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can. Respir. J. (2002) 9:417-423.
   PubMedGoogle Scholar
• HALTERMAN JS, MCCONNOCHIE KM, CONN KM et al.: A potential pitfall in provider assessments of the quality of asthma control. Ambul. Pediatr. (2003) 3:102-105.
   PubMedGoogle Scholar
• TEETER JG, BLEEKER ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest (1998) 113:272-277.
   PubMed Web of Science ®Google Scholar
• CALHOUN W, SUTTON LB, EMMETT A et al.: Asthma variability in patients previously treated with β2-agonists alone. J. Allergy Clin. Immunol. (2003) 112:1088-1094.
   PubMed Web of Science ®Google Scholar
• CHIPPS BE, SPAHN JD, SORKNESS CA et al.: Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting β-agonists. J. Pediatr. (2006) 148:517-521.
   PubMedGoogle Scholar
• BOULET LP, BOULET V, MILOT JP: How should we quantify asthma control? A proposal. Chest (2002) 122:2217-2223.
   PubMed Web of Science ®Google Scholar
• SZEFLER SJ, PHILLIPS BR, MARTINEZ FD et al.: Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. (2005) 115:233-242.
   PubMed Web of Science ®Google Scholar
• MALMSTROM K, RODRIGUEZ-GOMEZ G, GUERRA J et al.: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann. Intern. Med. (1999) 130:487-495.
   PubMed Web of Science ®Google Scholar
• SZEFLER SJ, MARTIN RJ, KING TS et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. (2002) 109:410-418.
   PubMed Web of Science ®Google Scholar
• TANTISIRA KG, LAKE S, SILVERMAN ES et al.: Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. (2004) 13:1353-1359.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, CHINCHILLI VM, FORD JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 364:1505-1512.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, DRAZEN JM, LIGGETT SB et al.: The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. (2000) 162:75-80.
   PubMed Web of Science ®Google Scholar
• WECHSLER ME, LEHMAN E, LAZARUS SC et al.: β-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. (2006) 173:519-526.
   PubMed Web of Science ®Google Scholar
• DRYSDALE CM, MCGRAW DW, STACK CB et al.: Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA (2000) 97:10483-10488.
   PubMed Web of Science ®Google Scholar
• LIMA JJ, ZHANG S, GRANT A et al.: Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. (2006) 173:379-385.
   PubMed Web of Science ®Google Scholar
• SILVERMAN ES, DRAZEN JM: Genetic variations in the 5-lipoxygenase core promoter. description and functional implications. Am. J. Respir. Crit. Care Med. (2000) 161:A402.
   Google Scholar
• JATAKANON A, LIM S, BARNES PJ: Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med. (2000) 161:64-72.
   PubMed Web of Science ®Google Scholar
• DEYKIN A, LAZARUS SC, FAHY JV et al.: Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J. Allergy Clin. Immunol. (2005) 115:720-727.
   PubMed Web of Science ®Google Scholar
• GREEN RH, BRIGHTLING CE, MCKENNA S et al.: Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet (2002) 360:1715-1721.
   PubMed Web of Science ®Google Scholar
• KHARATONOV SA, GONIO F, KELLY C et al.: Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur. Respir. J. (2003) 21:433-438.
   Google Scholar
• BERRY MA, SHAW DE, GREEN RH et al.: The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin. Exp. Allergy (2005) 35:1175-1179.
   PubMed Web of Science ®Google Scholar
• SMITH AD, COWAN JO, BRASSETT KP et al.: Use of enhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med. (2005) 352:2163-2173.
   PubMed Web of Science ®Google Scholar
• SONT JK, WILLEMS LN, BEL EH et al.: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am. J. Respir. Crit. Care Med. (1999) 159:1043-1051.
   PubMed Web of Science ®Google Scholar
• MACGLASHAN Jr DW, BOCHNER BS, ADELMAN DC et al.: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. (1997) 158:1438-1445.
   PubMed Web of Science ®Google Scholar
• BECK LA, MARCOTTE GV, MACGLASHAN D, TOGIAS A, SAINI S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J. Allergy Clin. Immunol. (2004) 114:527-530.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, BEASLEY R, AYRES J et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 60:309-316.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J, CABRERA P, BERKMAN N et al.: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 60:302-308.
   PubMed Web of Science ®Google Scholar
• CORRY DB, KHERADMAND F: Control of allergic airway inflammation through immunomodulation. J. Allergy Clin. Immunol. (2006) 117:8461-8464.
   Google Scholar
• CRETICOS PS, SCHROEDER JT, HAMILTON RG et al. Immunotherapy with a ragweed–toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. (2006) 355:1445-1455.
   PubMed Web of Science ®Google Scholar
• HOWARTH PH, BABU KS, ARSHAD HS et al.: Tumour necrosis factor (TNF-α) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax (2005) 60:1012-1018.
   PubMed Web of Science ®Google Scholar
• BERRY MA, HARGADON B, SHELLEY M et al.: Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med. (2006) 354:697-708.
   PubMed Web of Science ®Google Scholar
• THOMAS PS: Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol. Cell Biol. (2001) 79:132-140.
   PubMed Web of Science ®Google Scholar
• THOMAS PS, HEYWOOD G: Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax (2002) 57:774-778.
   PubMed Web of Science ®Google Scholar
• ALLEN DB, BIELORY L, DERENDORF H, DLUHY R, COLICE GL, SZEFLER SJ: Inhaled corticosteroids: past lessons and future issues. J. Allergy Clin. Immunol. (2003) 112:S1-S40.
   PubMedGoogle Scholar
• ROHATAGI S, APPAJOSYULA S, DERENDORF H et al.: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. (2004) 44:37-47.
   PubMed Web of Science ®Google Scholar
• JACKSON LD, POLYGENIS D, MCIVOR RA, WORTHINGTON I: Comparative efficacy and safety of inhaled corticosteroids in asthma. Can. J. Clin. Pharmacol. (1999) 6:26-37.
   PubMedGoogle Scholar
• BELVISI MG: Preclinical pharmacology of ciclesonide. Eur. Respir. Rev. (2004) 13:66-68.
   Google Scholar
• ROHATAGI S, ARYA V, ZECH K et al.: Population pharmacokinetics and pharmacodynamics of ciclesonide. J. Clin. Pharmacol. (2003) 43:365-378.
   PubMed Web of Science ®Google Scholar
• NAVE R, BETHKE TD, VAN MARLE SP, ZECH K: Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. (2004) 43:479-486.
   PubMed Web of Science ®Google Scholar
• DYER MJ, HALPIN DMG, STEIN K: Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam. Pract. (2006) 7:34.
   PubMedGoogle Scholar
• WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. (2002) 87:2160-2163.
   PubMed Web of Science ®Google Scholar
• DEROM E, VAN DE WELDE V, MARISSENS S et al.: Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm. Pharmacol. Ther. (2005) 18:328-336.
   PubMed Web of Science ®Google Scholar
• HANSEL TT, BENEZET O, KAFÉ H et al.: A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin. Ther. (2006) 28:906-920.
   PubMed Web of Science ®Google Scholar
• KALINER MA: Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin. Ther. (2006) 28:319-331.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MATERA MG, LUTVALL J: Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2005) 14:775-785.
   PubMed Web of Science ®Google Scholar
• PAGE CP, MORLEY J: Contrasting properties of albuterol stereoisomers. J. Allergy Clin. Immunol. (1999) 104:S31-S41.
   Google Scholar
• BUNDSCHUH DS, ELTZE M, BARSIG J, WOLLIN L, HATZELMANN A, BEUME R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. (2001) 297:280-290.
   PubMed Web of Science ®Google Scholar
• HATZELMANN A, SCHUDT C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. (2001) 297:267-279.
   PubMed Web of Science ®Google Scholar
• ZECH K, DAVID M, SEIBERLING M, WEIMAR C, BETHKE T, WURST W: High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor. Eur. Respir. J. (2001) 18(Suppl. 33):20S.
   Google Scholar
• BOUSQUET J, AUBIER M, SASTRE J et al.: Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy (2006) 61:72-78.
   PubMed Web of Science ®Google Scholar
• AKBARI O: The role of iNKT cells in development of bronchial asthma: a translational approach from animal models to human. Allergy (2006) 61:962-968.
   Google Scholar
• ZEIGER RS, SZEFLER SJ, PHILLIPS BR et al.: Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J. Allergy Clin. Immunol. (2006) 117:45-52.
   PubMed Web of Science ®Google Scholar